Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) EBIT: 2023-2025

Historic EBIT for Tonix Pharmaceuticals Holding (TNXP) over the last 2 years, with Sep 2025 value amounting to -$33.1 million.

  • Tonix Pharmaceuticals Holding's EBIT fell 112.59% to -$33.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$99.9 million, marking a year-over-year increase of 29.43%. This contributed to the annual value of -$136.7 million for FY2024, which is 15.48% down from last year.
  • As of Q3 2025, Tonix Pharmaceuticals Holding's EBIT stood at -$33.1 million, which was down 16.86% from -$28.3 million recorded in Q2 2025.
  • Over the past 5 years, Tonix Pharmaceuticals Holding's EBIT peaked at -$15.6 million during Q3 2024, and registered a low of -$77.3 million during Q2 2024.
  • Moreover, its 3-year median value for EBIT was -$27.3 million (2023), whereas its average is -$30.0 million.
  • The largest annual percentage gain for Tonix Pharmaceuticals Holding's EBIT in the last 5 years was 63.40% (2025), contrasted with its biggest fall of 112.59% (2025).
  • Quarterly analysis of 3 years shows Tonix Pharmaceuticals Holding's EBIT stood at -$27.3 million in 2023, then increased by 17.74% to -$22.5 million in 2024, then slumped by 112.59% to -$33.1 million in 2025.
  • Its EBIT was -$33.1 million in Q3 2025, compared to -$28.3 million in Q2 2025 and -$16.1 million in Q1 2025.